Downregulation of E-cadherin is a crucial event for epithelial to mesenchymal transition (EMT) in embryonic development and cancer progression. Using the EpFosER mammary tumour model we show that during EMT, upregulation of the transcriptional regulator deltaEF1 coincided with transcriptional repression of E-cadherin. Ectopic expression of deltaEF1 in epithelial cells was sufficient to downregulate E-cadherin and to induce EMT. Analysis of E-cadherin promoter activity and chromatin immunoprecipitation identified deltaEF1 as direct transcriptional repressor of E-cadherin. In human cancer cells, transcript levels of deltaEF1 correlated directly with the extent of E-cadherin repression and loss of the epithelial phenotype. The protein was enriched in nuclei of human cancer cells and physically associated with the E-cadherin promoter. RNA interference-mediated downregulation of deltaEF1 in cancer cells was sufficient to derepress E-cadherin expression and restore cell to cell adhesion, suggesting that deltaEF1 is a key player in late stage carcinogenesis.
Introduction
The epithelial cell-cell adhesion protein E-cadherin is a potent suppressor of tumour cell invasion and metastasis (Cavallaro et al., 2002; Conacci-Sorrell et al., 2002; Wheelock and Johnson, 2003) . Tumour cells lose or acquire invasive properties when E-cadherin-mediated adhesion is increased or inhibited, respectively (Behrens et al., 1989; Frixen et al., 1991; Vleminckx et al., 1991) . In line with these findings ectopic expression of Ecadherin in a transgenic mouse model prevented tumour cell invasion and metastasis (Perl et al., 1998) . Although mutations of the E-cadherin gene have been found in specific subtypes of cancers, the incidence of such mutations in carcinogenesis is low (Risinger et al., 1994; Berx et al., 1995; Guilford et al., 1998) . Loss of E-cadherin in cancer cells frequently involves transcriptional repression (Strathdee, 2002; Thiery, 2002) . This includes epigenetic modifications, such as CpG island hypermethylation of the E-cadherin regulatory promoter (Graff et al., 1995; Grady et al., 2000) , as well as repression by specific transcription factors, including Snail (Batlle et al., 2000; Cano et al., 2000; Guaita et al., 2002; Peinado et al., 2004b) , Slug (Hajra et al., 2002; Bolos et al., 2003) , Smad-interacting protein 1 (SIP1, ZEB2) (Comijn et al., 2001 ) and the helix-loop-helix factor E12/E47 (Perez-Moreno et al., 2001; Bolos et al., 2003) .
Downregulation of E-cadherin is often accompanied by a conversion of epithelial cells to migratory, fibroblastoid cells, a process collectively referred to as epithelial-mesenchymal transition (EMT). In nonpathological conditions, EMT occurs during well-defined stages of embryonic development, tissue repair and reorganization (Hay, 1995) . In the past years, however, EMT has been increasingly recognized as a key event in the progression of tumour cells to dedifferentiated and invasive phenotypes (Birchmeier et al., 1996; Thiery, 2002; Grunert et al., 2003; Gotzmann et al., 2004) . Various signalling proteins, such as receptor tyrosine kinases, small GTPases, MAP kinases, integrin-linked kinase (ILK), PI3-kinase, TGF-b and c-Fos, as well as matrix-metalloproteinases and extracellular matrix components have been implicated in the regulation of EMT and tumour progression, but crosstalks between these pathways, their downstream targets, and their causal relations to different steps of tumour development remain largely elusive (Birchmeier et al., 1996; Thiery, 2002; Grunert et al., 2003; Gotzmann et al., 2004) . Many of the signalling pathways interfere with the function and/or expression of E-cadherin, but in most cases downstream effectors directly controlling Ecadherin function and expression are still unknown. Snail is the only protein that has recently been implicated in TGFb-, and ILK-dependent downregulation of E-cadherin (Tan et al., 2001; Peinado et al., 2003) .
Several previously reported properties make the zinc-finger-and homeobox-containing transcriptional regulator delta-crystallin enhancer-binding factor 1 (deltaEF1, also known as ZEB1), a close homolog of SIP1 ), a potential candidate for a regulator of E-cadherin expression. First, expression of deltaEF1 during development and in the adult is restricted to E-cadherin-negative tissues of mesodermal origin and of neural crest derivatives (Funahashi et al., 1993) . Second, deltaEF1 bound to a short fragment of the E-cadherin promoter in vitro (Grooteclaes and Frisch, 2000) . Third, deltaEF1 caused repression of luciferase reporter constructs driven by the E-cadherin proximal regulatory promoter region (Grooteclaes and Frisch, 2000) . However, despite these findings a direct evidence for deltaEF1 being a bona fide E-cadherin repressor in vivo is still lacking and, more importantly, its role in epithelial physiology and differentiation is completely elusive.
In this paper, we show that deltaEF1 is upregulated during EMT in a cell culture tumour model and that ectopic expression of deltaEF1 in epithelial cells is sufficient to downregulate endogenous E-cadherin and to induce EMT on its own. Most importantly, we show that deltaEF1 directly represses E-cadherin in human tumour cells and that knockdown of deltaEF1 expression in breast cancer cells by RNA interference (RNAi) is sufficient to induce expression of E-cadherin.
Results

Expression of deltaEF1 is induced during EMT
EpFosER mouse mammary epithelial cells represent an inducible tumour model system that has been used successfully to unravel molecular mechanisms governing EMT (Eger et al., 2000; Stockinger et al., 2001; Eger et al., 2004) . The cells constitutively express a fusion protein of c-Fos and the hormone-binding domain of the oestrogen receptor. While these cells exhibit a fully polarized epithelial phenotype in the absence of the hormone, they undergo EMT in a highly synchronous manner upon oestradiol-dependent activation of the fusion protein (Eger et al., 2000) . Molecular events underlying FosER-induced EMT include loss of apicobasolateral polarity and growth in multilayers (2 days after FosER activation), downregulation of E-cadherin (3-5 days) and the formation of undifferentiated fibroblastoid cells expressing a variety of mesenchymal marker proteins (10 days). In addition, activation of the FosER fusion protein in vitro strongly enhanced the tumourigenic and metastatic potential of the cells in SCID mice (our unpublished data). In order to identify FosER target genes that interfere with E-cadherin expression and epithelial polarity, we have performed a comprehensive analysis of the genetic programme of EpFosER cells at morphologically defined stages of EMT. Polysome-bound mRNA representing actively translated RNA (Mikulits et al., 2000) was prepared 12, 24, 48, 96 and 240 h after FosER activation and used for Affymetrix GeneChip s analyses. Among the differentially regulated genes, we identified the transcriptional regulator deltaEF1, whose RNA level was elevated fourfold after 12 h of FosER activity and increased up to 12-fold after 96 h (Figure 1a ). Oestradiol treatment of the parental EpH4 mammary epithelial cells for 48 h was not sufficient to induce deltaEF1 expression, indicating that upregulation of deltaEF1 is dependent on the activity of the FosER fusion protein (Figure 1a) .
A direct comparison of total E-cadherin and deltaEF1 RNA and protein by RT-PCR and immunoblotting, respectively, revealed that upregulation of deltaEF1 expression coincided with the downregulation of E-cadherin mRNA and protein levels during EMT (Figure 1b and c) . In contrast to deltaEF1, the expression of Snail and SIP1, two previously described transcriptional repressors of E-cadherin, remained largely unaltered within the first 4 days of EMT (Figure 1b ). Transcript levels of these genes were elevated only upon long-term FosER activation ( Figure 1b , 240 h oestradiol treatment).
Next, we investigated whether deltaEF1 is capable of interfering with E-cadherin promoter activity using luciferase reporter constructs that contained the À319/ þ 56 or the À178/ þ 92 fragment of the murine E-cadherin proximal regulatory promoter. Transient expression of deltaEF1 in differentiated epithelial EpFosER cells resulted in strong downregulation of the activities of both luciferase reporter genes ( Figure 1d ). Thus, deltaEF1 is a prime candidate for downregulating E-cadherin expression during FosERinduced EMT. 
DeltaEF1 represses transcription of endogenous E-cadherin
To test whether deltaEF1 is a bona fide repressor of endogenous E-cadherin in mammary epithelial cells, we generated epithelial EpFosER cell clones stably expressing GFP-or FLAG-tagged deltaEF1 by retroviral infection. DeltaEF1-expressing cell clones (EpdEF1-GFP or EpdEF1-FLAG) showed a dramatic change in morphology compared to mock-transfected (EpGFP) or untransfected control cells. While mock-transfected cells formed epithelial cell clusters at low density and coherent epithelial monolayers in confluent cultures, deltaEF1-expressing cells were unable to form extensive cell to cell contacts (Figure 2a) . At lower densities, the cells formed long and thin protrusions (Figure 2a) , reminiscent of the mesenchymal EpFosER phenotype (Eger et al., 2000) . At higher densities, the cells formed irregular cell aggregates with cells frequently growing in multilayers (Figure 2a Equal amounts of cell lysates were transferred to nitrocellulose and probed with antibodies against E-cadherin, GFP and Actin (loading control). The GFP-specific antibody was used to demonstrate expression of the exogenous deltaEF1-GFP fusion protein. EpdEF1-GFP1, EpdEF1-GFP2 and EpdEF1-GFP3 cells represent three independently generated deltaEF1-GFP-expressing stable cell clones. Note, only the molecular weight region of deltaEF1-GFP is shown in the immuoblot with the GFP antibody.
(d) Cells were analysed by RT-PCR to determine E-cadherin transcript levels. The expression of Actin is shown as loading control
DeltaEF1 represses E-cadherin in human cancer cells A Eger et al
We next analysed expression and intracellular localization of E-cadherin. In mock-transfected cells, Ecadherin was detected exclusively at lateral cell-cell contact sites (Figure 2b ). However, deltaEF1-expressing cells did not exhibit a significant E-cadherin-specific staining at the cell periphery ( Figure 2b) . A weak staining of the protein could only be detected at perinuclear regions (Figure 2b ). Immunoblot analyses of total cell lysates confirmed that E-cadherin protein levels were strongly downregulated in three independent clones of EpdEF1-GFP versus control cells ( Figure 2c ). As tested by RT-PCR analyses, E-cadherin mRNA levels also were strongly reduced (Figure 2d ), suggesting that E-cadherin was repressed on the transcriptional level.
To assess whether the depletion of E-cadherin transcripts is due to repression of the E-cadherin proximal regulatory promoter, we performed reporter gene assays in the stable transfectants. Stable expression of deltaEF1-GFP fusions or Flag-tagged proteins significantly reduced the E-cadherin promoter activities of the À178/ þ 92 and the À319/ þ 56 reporter gene compared to mock-transfected epithelial cells ( Figure 3a ).
Mutations within E-box 3 or the more upstream E-pal element in reporter constructs containing a À178 to þ 92 E-cadherin promoter fragment (Bolos et al., 2003) had only minor effects on deltaEF1-dependent repression, but mutations in both E-box elements interfered with repression of the reporter gene ( Figure 3b ). Thus, mutation of both E-boxes is required to efficiently interfere with the repressive activity of deltaEF1.
DeltaEF1 associates with the E-cadherin promoter in vivo
So far we have shown that deltaEF1 repressed E-cadherin promoter reporter constructs and caused downregulation of endogenous E-cadherin in epithelial cells. To demonstrate that deltaEF1 interacts directly with the endogenous E-cadherin promoter at the chromatin level, we performed chromatin immunoprecipitation (ChIP) experiments. A deltaEF1 antibody directed against the amino-terminus as well as a GFP antiserum efficiently pulled down deltaEF1-GFP protein complexes together with chromatin fragments comprising the À132 to þ 63 E-cadherin proximal regulatory promoter region ( Figure 3c ). An antibody against the deltaEF1 carboxy-terminal region was only weakly effective in immunoprecipitation, whereas unrelated mouse antibodies or beads alone did not precipitate E-cadherin promoter fragments (Figure 3c ). Thus, deltaEF1 physically associated with the E-cadherin proximal promoter in vivo and could therefore function as a direct transcriptional repressor of E-cadherin.
DeltaEF1 affects expression and localization of epithelial and mesenchymal marker proteins
Next, we analysed the phenotype of deltaEF1-expressing cells in more detail focusing on the expression and intracellular localization of epithelial and mesenchymal marker proteins. Cells were grown to confluency and junctional complexes were analysed by immunofluorescence microscopy using antibodies to ZO-1 (Tight 
Figure 3 DeltaEF1 is a direct transcriptional repressor of Ecadherin. (a) Three independent clones of deltaEF1-GFP and deltaEF1-Flag cells, and GFP-expressing cells were transfected with the murine E-cadherin reporter constructs pGL2-E-cad (À178 to þ 92, wild-type sequence) and pGL3-Ecad (À319 to þ 56, wildtype sequence). Measured luciferase activities were normalized to b-galactosidase expression. White bars represent pGl2-E-cad and grey bars pGL3-E-cad luciferase activities in stable clones relative to GFP control cells (black bar). Bars represent standard deviation (b) Cells stably expressing deltaEF1-Flag1 were transfected with wild-type or mutated pGL2-E-cad reporter constructs. The wildtype promoter construct contained a À178 to þ 92 fragment of the murine E-cadherin proximal promoter (wt), whereas the mutated versions contained base pair substitutions either at the proximal Ebox element (E-box3*), the distal palindromic E-boxes (E-pal*) or at both sites (Epal* þ E-box3*) Bolos et al., 2003) . Bars represent standard deviation. (c) DeltaEF1 associates with the E-cadherin promoter at the chromatin level. Cells expressing deltaEF1 (EpdEF1-GFP) were subjected to ChIP analyses using antibodies to deltaEF1 (C-terminal epitope, dEF1-CT; N-terminal epitope, dEF1-NT) and GFP. Unrelated mouse antibodies were used in the control fraction. The amplified mouse E-cadherin promoter fragment is shown (À132 to þ 62)
DeltaEF1 represses E-cadherin in human cancer cells A Eger et al junctions) and Desmoplakin (Desmosomes). In contrast to their peripheral localization at cell-cell contact sites in GFP-expressing epithelial cells, both proteins were diffusely distributed throughout the cytoplasm in deltaEF1-expressing cells (Figure 4a ). The overall ZO-1 protein level was significantly reduced, whereas the amount of Desmoplakin I þ II was comparable to that of mock-transfected epithelial cells (Figure 4a ). Thus, deltaEF1-induced epithelial dedifferentiation includes both delocalization and downregulation of epithelial proteins. In addition, ectopic expression of deltaEF1 caused a strong induction of the mesenchymal marker protein Vimentin (Figure 4b) . Interestingly, N-cadherin protein levels were also upregulated in the fibroblastoid cell cultures (Figure 4b ). N-cadherin has previously been shown to promote cell migration and tumour progression and to accumulate in E-cadherin-negative tumour cells (Hazan et al., 2000; Tomita et al., 2000) . Altogether, expression of deltaEF1 in epithelial cells was sufficient to induce hallmarks of EMT, such as downregulation of E-cadherin and ZO-1, disintegration of cell-cell junctions and induction of mesenchymal marker proteins.
DeltaEF1 represses E-cadherin in human breast cancer cells
Loss of E-cadherin expression in human tumours is frequently associated with poor prognosis and survival, most likely due to enhanced invasiveness and metastasis (Cavallaro and Christofori, 2004) . To test whether deltaEF1 mediates transcriptional repression of Ecadherin in human tumour cells, we first performed real-time PCR to examine the expression of deltaEF1 and E-cadherin in a panel of 19 human cell lines derived from normal breast (one), fibrocystic disease (two) or breast cancer (16). The selected cells reflect many features of cancer cells in vivo and have been intensively used as tumour models in the last years (Lacroix and Leclercq, 2004) . Interestingly, tumour cells that expressed high levels of deltaEF1 exhibited very low or undetectable levels of E-cadherin transcripts ( Figure 5 ). Conversely, all E-cadherin-positive cells had strongly reduced deltaEF1 mRNA levels ( Figure 5 ). Thus, there exists a strong inverse correlation between expression of deltaEF1 and E-cadherin. Expression of Snail did not strictly correlate with E-cadherin downregulation, suggesting that deltaEF1, rather than Snail is a key regulator of E-cadherin expression in these human tumour cells. This is consistent with the high deltaEF1 protein levels detected in the nuclei of E-cadherinnegative MDA-MB-231 (Figure 6b ) or CAMA-1 cells (data not shown), whereas E-cadherin-positive cells, such as ZR-75-1, completely lacked nuclear deltaEF1 (Figure 6b ). Moreover, all cells with high deltaEF1 levels exhibited a rather undifferentiated and spindleshaped morphology (Figure 6a ; compare also with Lacroix and Leclercq, 2004) . To support the model that deltaEF1 can serve as a direct transcriptional repressor of E-cadherin in these cancer cells, we performed deltaEF1-specific ChIP experiments in MDA-MB-231 cells, which lack E-cadherin, and ZR-75-1 cells, which express high amounts of E-cadherin ( Figure 5 and 6b) . Unlike unrelated mouse antibodies, two deltaEF1-specific antibodies coprecipitated chromatin fragments of the human E-cadherin promoter in MDA-MB-231 cells, whereas the same antibodies could not bring down the promoter region in ZR-75-1 cells (Figure 7a ). Thus, like ectopic deltaEF1 in murine cells (Figure 3c ), endogenously expressed deltaEF1 in cancer cells directly associated with the E-cadherin promoter in vivo (Figure 7a ). These data suggest that deltaEF1 represents a major regulator of E-cadherin transcription in human tumour cells. To test this model on a functional level, we employed RNA interference (RNAi) to knock down endogenous deltaEF1 protein in cancer cells. Small interfering RNA (siRNA) targeting deltaEF1, or unrelated control siRNA (Rhodamine-conjugated or LaminA-specific) were transfected into MDA-MB-231 cells and expression of E-cadherin and deltaEF1 was analysed 3 days after transfection. Immunoblotting of total cell lysates revealed a significant decrease of deltaEF1 protein levels upon treatment with the deltaEF1-specific siRNA (Figure 7b ). In the same cells, expression of E-cadherin was highly induced, both on the RNA as well as on the protein level (Figure 7b ). E-cadherin accumulated at the plasma membrane and was strongly enriched at sites of cell-cell contact (Figure 7c) . The E-cadherin-expressing cells had often lost their fibroblastoid morphology and exhibited a wellspread, epithelial-like morphology. Thus, inhibition of a single transcriptional regulator was sufficient to reactivate expression of a silenced E-cadherin gene in cancer cells.
Discussion
DeltaEF1 -a novel member of the E-cadherin repressor family
DeltaEF1 (zfh1) and the related gene SIP1 (zfh2) were first isolated from a Drosophila cDNA expression library (Fortini et al., 1991) . Both proteins contain two C2H2 (Kru¨ppel)-type zinc-finger clusters at their C-and N-termini as well as a central homeobox domain . Ectopic expression of SIP1 was recently found to reduce E-cadherin expression in canine epithelial cells (MDCK) (Comijn et al., 2001) . Also deltaEF1 was shown to interact with the E-cadherin promoter in vitro and to repress E-cadherin promoter activity in reporter gene assays (Grooteclaes and Frisch, 2000) . However, the physiological significance of these in vitro data remained completely elusive.
In this paper, we show that stable expression of deltaEF1 in mammary epithelial cells was sufficient to cause downregulation of endogenous E-cadherin mRNA and protein levels. Our findings strongly argue that deltaEF1 directly inhibits E-cadherin transcription, as deltaEF1 physically associated with the E-cadherin promoter at the chromatin level in vivo. In addition, we found that deltaEF1 induced EMT in epithelial cells including strong induction of Vimentin and N-cadherin and downregulation or relocalization of the epithelial proteins ZO-1 and Desmoplakin. Although E-cadherin silencing is considered a hallmark of EMT, it is most likely not sufficient to induce expression of N-cadherin or Vimentin. Thus, deltaEF1 might regulate the expression of various other proteins important for epithelial plasticity.
Two other zinc-finger proteins lacking homeobox domains, Snail and Slug, as well as the basic helix-loophelix (bHLH) factor E47 have been reported to repress expression of E-cadherin in different cell lines (Batlle et al., 2000; Cano et al., 2000; Perez-Moreno et al., 2001; Guaita et al., 2002; Hajra et al., 2002; Bolos et al., 2003) . Repressive activity of Snail, Slug as well as SIP1 was dependent on the integrity of E-box elements in the E-cadherin proximal promoter region (Batlle et al., 2000; Comijn et al., 2001; Hajra et al., 2002) . Likewise, we could show that mutation of both E-boxes is required to significantly affect deltaEF1-mediated repression. At present it is unclear whether different repressor molecules can bind to adjacent E-box elements simultaneously and repress transcription in a cooperative manner or whether the proteins function individually in a cell-type and tissue-specific manner. In addition to proximal E-box elements, a complex interplay of multiple regulatory regions dispersed throughout large parts of the E-cadherin locus has been identified recently in transgenic mice (Stemmler et al., 2003) . Thus, the functional characterization of the different repressor molecules on the chromatin level in vivo represents a major challenge of future research. In this context it remains to be demonstrated whether SIP1, Slug and E47 can directly bind to the E-cadherin promoter at the (Peinado et al., 2004a) and deltaEF1 (this study), or whether these proteins exert their repressive effects on E-cadherin transcription via indirect mechanisms.
DeltaEF1 and cancer progression
During the last decade E-cadherin has increasingly been recognized as a potent tumour suppressor protein (Okegawa et al., 2002) . Inactivation of the E-cadherin/ catenin adhesion complex usually correlates with poor prognosis and survival of cancer patients, most likely due to reinforced invasion and metastasis of tumour cells (Conacci-Sorrell et al., 2002; Cavallaro and Christofori, 2004) . Interestingly, germline or sporadic mutations that affect E-cadherin functions are rather uncommon in human cancers (Strathdee, 2002) . In most cases, transcriptional repression of E-cadherin or decreased protein stability account for the diminished E-cadherin levels in human tumours (Thiery, 2002) . DeltaEF1-specific siRNA (siRNA-dEF1) was used to reduce the protein levels of endogenous deltaEF1 in MDA-MB-231 cells. Control cells were treated with unrelated Lamin A-specific (Control1) or Fluorophore-conjugated (Control2) siRNA. The efficiency of deltaEF1 protein knockdown and expression of Ecadherin was monitored by immunoblot analysis of cell lysates, using antibodies against deltaEF1 (N-terminal epitope, E20) and Ecadherin. Antibodies to Actin were used to confirm equal loading.
Derepression of E-cadherin at the transcriptional level was shown by RT-PCR analyses. Actin was used as loading control. (c) Immunofluorescence microscopic detection of E-cadherin in MDA-MB-231 cells after treatment with deltaEF1-specific siRNA (siRNA-dEF1) or unrelated Lamin A-specific siRNA (Control). Confocal images are shown. Bar, 10 mm
DeltaEF1 represses E-cadherin in human cancer cells A Eger et al human breast cancer cell lines, we were unable to find a clear correlation of Snail expression and the downregulation of E-cadherin on the transcriptional level. Thus, expression of Snail is not always sufficient to block E-cadherin transcription and may require coexpression of other repressor molecules such as deltaEF1. Squamous cell carcinoma cells, for example, exhibited elevated levels of both, deltaEF1 and Snail, which were accompanied by a strong reduction of E-cadherin protein levels and upregulation of mesenchymal marker proteins (Taki et al., 2003) . Interestingly, ectopic expression of Snail in various cell lines can result in induction of deltaEF1 expression (Guaita et al., 2002; Taki et al., 2003) . Likewise, Snail was essential for proper expression of deltaEF1 during mesoderm formation in Drosophila embryonic development (Lai et al., 1993) . In this paper, we could show a strict inverse correlation of deltaEF1 and E-cadherin expression in a collection of 19 human cell lines, most of them derived from breast cancer patients. Cells expressing elevated levels of deltaEF1 lacked E-cadherin and were unable to form epithelial cell sheets (for a detailed description of breast cancer cell lines used in this study, see Lacroix and Leclercq, 2004) . Most importantly, a series of results shown here demonstrate a direct role of deltaEF1 in E-cadherin downregulation in these human tumour cells: First, in line with the RNA expression data, high protein levels of deltaEF1 were detected only in nuclei of E-cadherin-negative cells. Second, deltaEF1 directly associated with the E-cadherin promoter at the chromatin level in vivo. Third, downregulation of deltaEF1 by RNAi led to derepression of the E-cadherin promoter on the transcriptional level and accumulation of E-cadherin at the plasma membrane. For this reason deltaEF1 might enhance the malignant conversion of tumour cells to invasive and metastatic phenotypes. In line with our findings, a recent paper has also implied deltaEF1 in E-cadherin repression in lung cancer cells (Ohira et al., 2003) .
Thus, during cancer progression deltaEF1 could function as a molecular switch allowing tumour cells to change phenotypes rapidly and frequently. This might contribute to the cellular heterogeneity of tumours and explain the dynamics of E-cadherin expression in different regions of solid tumours and at metastatic lesions. DeltaEF1 and functionally related Ecadherin repressor molecules might regulate distinct stages of metastasis, such as initial dedifferentiation of primary tumour cells, the maintenance of the migratory and/or undifferentiated phenotype, and the rate of redifferentiation and settlement at distinct tissues and organs. However, further studies in tumour samples and cell systems will be required for a better understanding of the diverse roles of these transcriptional repressors in tumour formation, progression and metastasis.
Materials and methods
Cell culture
EpFosER and EpH4 cells were cultivated as described previously (Reichmann et al., 1989; Eger et al., 2000) .
EpdEF1-GFP, EpdEF1-Flag and EpGFP cells were cultivated in DMEM and 10% FCS as described for the parental cells (Eger et al., 2000) . Human cell lines were cultivated in media recommended by the American Type Culture Collection (ATCC).
DNA GeneChips
Polysome-bound poly(A)
þ RNA was harvested as described previously (Mikulits et al., 2000) . Biotin-labelled cRNA for hybridization was prepared as described, using polysomebound RNA fractions (Fambrough et al., 1999; Damm et al., 2001) . Fragmented cRNA (10 mg) in 200 ml hybridization solution were hybridized onto the Affymetrix GeneChip Mu11k array set (sub A, B), representing over 11 000 known murine genes and ESTs. Images were scanned at 3 mm resolution using a Hewlett-Packard GeneArray Scanner, and analysed using Affymetrix GeneChip software. Experiments were performed in triplicates, using independently isolated mRNA preparations derived from different cell harvests.
Construction of deltaEF1 expression plasmids
The GFP-or FLAG-tag was inserted into the EcoRI and SalI sites of the pBabe-puro (Morgenstern and Land, 1990) expression vector. To allow rapid generation of GFP and FLAG fusion proteins, we inserted the Cassette B of the Gateway cloning system (Invitrogen, Carlsbad, USA) into the SnaBI site located upstream of GFP and FLAG. Full-length deltaEF1 cDNA was amplified using pCS3mDeltaEF1FL vector (Funahashi et al., 1993) as a template (Primer: forward 5 0 -CACCATGGCGGATGGCCCCAGGTG-3 0 ; reverse 5 0 -AGCTTCATTTGTCTTCTCTTCAG-3 0 ) and cloned into the Gateway Entry Vector pENTR/D-TOPO. To create Cterminally tagged fusion proteins, deltaEF1 was shuttled from the pENTR/D-TOPO entry vector into the Gateway compatible destination vector pBabe-puro-GFP or -FLAG via the Gateway LR-reaction according to the manufacturer's instructions.
Retroviral infection and generation of stable cell clones
The helper-free, ecotropic Phoenix packaging cell line was transfected with the deltaEF1 retroviral expression constructs using Lipofectamine 2000 (Invitrogen, Carlsbad, USA). Cells were cultivated for 30 h at 321C and supernatants (supplemented with 5 mg/ml Polybrene) were used to infect EpFosER mammary epithelial cells. Target cells were incubated for 48 h at 371C in the presence of retroviral particles and for another day in fresh medium. Puromycin (5 mg/ml) was applied to the cultures to select for deltaEF1-expressing cells. DeltaEF1-GFP transfectants were further enriched by Fluorescence-Activated Cell Sorting. Three independent deltaEF1-GFP as well as deltaEF1-FLAG subclones were obtained by limited dilution. These cell clones were used for all experiments.
Reporter gene assays
The mouse À319/ þ 56 E-cadherin promoter fragment was amplified by PCR and directionally cloned into the SacI and BglII sites of the pGL3 reporter vector (pGL3-Ecad). The mouse À178/ þ 92 E-cadherin promoter sequences in its wildtype and mutant E-box versions were excised by XbaI from the chloramphenicol acetyltransferase (CAT) reporter gene Bolos et al., 2003) and cloned into the NheI site of pGL2 reporter vector (pGL2-Ecad) (Bolos et al., 2003) . pGL2 and pGL3 reporter vectors were purchased from Invitrogen (Carlsbad, USA).
DeltaEF1 represses E-cadherin in human cancer cells A Eger et al E-cadherin promoter activity was determined in EpGFP and three EpdEF1-GFP-expressing cell clones. Cells were transfected with 2 mg pGL2-Ecad (wild-type) or 2 mg pGL3-Ecad reporter constructs together with 2 mg of the b-galactosidase expression construct pAD-CMV1 : b-Gal (Eger et al., 2000) to normalize for transfection. DeltaEF1-Flag1 cells were transfected with 2 mg of wild-type or mutated pGL2-Ecad reporter constructs Bolos et al., 2003) and 2 mg of pAD-CMV1 : b-Gal.
To test the repressive activity of transiently expressed deltaEF1 in epithelial EpFosER cells, the deltaEF1 expression vector pCS3mDeltaEF1FL was cotransfected with wild-type pGL3-Ecad or wild-type pGL2-Ecad. In all, 2 mg of pCS3mDeltaEF1FL (or empty control vector) and 1 mg of E-cadherin promoter reporter constructs and 1 mg of pAD-CMV1 : b-Gal were used for the assays. All transfections were performed in six-well plates with Lipofectamin 2000 (Invitrogen, Carlsbad, USA). Luciferase and b-galactosidase assays were performed 48 h after transfections as described previously (Eger et al., 2000) .
RT-PCR
Cells were lysed in TRIzol reagent (Invitrogen, Carlsbad, USA) and total RNA was prepared according to the manufacturer's instructions. Poly(A) þ RNA was prepared using the mRNA Isolation Kit (Roche, Mannheim, Germany) and cDNA was synthesized using the AMV first strand cDNA synthesis kit (Roche, Mannheim, Germany). cDNAs were used for PCR analysis using the puReTaq-Ready-To-Go PCR beads (Amersham Pharmacia Biotech, Uppsala, Sweden) and oligonucleotide primers specific for E-cadherin: forward 
Real-time PCR
For RNA isolation, cells were seeded at a density of B20 000 cells/cm 2 and incubated for 48 h. Medium was changed and cells were incubated for another 48 h to reach a cell density of around 70%. Medium was removed and cells were immediately lysed in Tri-Reagent (Sigma, St Louis, USA). Total RNA was prepared following the manufacturer's instructions and further purified using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA quality was assessed using the Bioanalyzer 2100 and the RNA 6000 nanoLabChip Kit (Agilent Technologies, Palo Alto, CA, USA). Only RNAs with a 28S : 18S ratio higher than 1.8 were used for reverse transcription. cDNA was prepared with cDNA High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). For the real-time PCR, the TaqMan s -system (Applied Biosystems, Foster City, CA, USA) with assay-on-demandt (Applied Biosystems) was used following the manufacturer's instructions (Tokuhiro et al., 2003) . Assay ID numbers: deltaEF1: Hs00611018_m1; Snail Hs00195591_m1, E-cadherin Hs00170423_m1. The relative expression of deltaEF1, Snail and E-cadherin was normalized to the amount of b-actin in the same cDNA using the standard curve method described by the manufacturer.
Antibodies
The following antibodies (Abs) were used: mouse monoclonal Abs against Desmoplakin I and II (Progen Biotechnik, Heidelberg, Germany), E-cadherin (Transduction Laboratories, Lexington, UK) and GFP (Roche, Mannheim, Germany); rat monoclonal Ab against ZO-1 (Chemicon, Temecula, USA); goat polyclonal Abs against deltaEF1 (ZEB-R17 and ZEB-E20) and N-cadherin (N19) (all Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); rabbit polyclonal Abs to N-cadherin (H-63), GFP (Clontech, Palo Alto, USA), Actin and Vimentin (both Sigma, St.Louis, USA); secondary Abs coupled to Alexa Fluor 488 (Molecular Probes, Inc., Eugene, OR, USA), Texas Red or Peroxidase (Jackson Laboratories, West-Grove, USA).
Immunofluorescence microscopy and immunoblotting
Cells were fixed in 2.5% formaldehyde (Merck, Inc., Whitehouse Station, NJ, USA) or methanol : acetone (1 : 1) and processed for immunofluorescence microscopy as described previously (Eger et al., 2000) . Samples were mounted in Mowiol and viewed on a ZEISS Axiovert 100M equipped with an LSM510 confocal microscope.
For immunblotting, total cell lysates obtained from equal amounts of cells were separated by SDS-PAGE. Electrotransfer of proteins onto nitrocellulose (0.2 mm, Schleicher and Schuell, Inc., Dassel, Germany) was carried out in 40 mM glycine, 48 mM Tris using the BioRad Mini Trans-blot system. Immunological detection of proteins was performed with the Super Signal ECL system (Pierce Chemical Company, Rockford, IL, USA).
CHIP assay
Cells were crosslinked with 1% formaldehyde (Merck, Inc., Whitehouse Station, NJ, USA) and processed for CHIP analyses using the CHIP Assay Kit from Upstate Biotechnlogy (Lake Placid, NY, USA). Samples were sonicated 10 times for 15 s in a SonoplusGM70 (Bandelin, Berlin, Germany) at cycle 90% and output 40%. Chromatin-antibody complexes were eluted from the ProteinA or ProteinG Sepharose beads (Amersham Pharmacia Biotech, Uppsala, Sweden) by addition of freshly prepared 1% SDS, 0.1 M NaHCO 3 and 10 mM dithiothreitol. Crosslinking was reversed by 5 M NaCl and incubation for 16 h at 651C. The DNA was extracted with phenol-chloroform, precipitated with ethanol and dissolved in water. PCR reactions were performed with the following primer: Murine E-cadherin promoter: forward 5 0 -AGACAGG GGTGGAGGAAGTT-3 0 , reverse 5 0 -GGGCAG GAGTCTA GCAGAAG-3 0 . Human E-cadherin promoter: forward 5 0 -A ACTCCA GGCTAGAGGGTCA-3 0 , reverse 5 0 -GGGCTGG AGTCTGAACTGA-3 0 .
RNA inhibition experiments
DeltaEF1-specific siRNA targets the sequence UGAUCAGC CUCAAUCUGCA of the human deltaEF1 mRNA. DeltaEF1-specific RNA oligonucleotides were purchased from RZPD (Deutsches Ressourcenzentrum fu¨r Genomforschung GmbH, Berlin, Germany) and control siRNA-Rhodamine and LaminA-specific siRNA were purchased from Quiagen (Qiagen, Hilden, Germany). RNA was transfected into MDA-MB-231 cells using Oligofectamine (Invitrogen, Carlsbad, USA) according to the manufacturers' instructions. Cells were processed for immunofluorescence and immunoblot analyses 3 days after transfection.
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